Loading clinical trials...
Loading clinical trials...
Genomic and Proteomic Study of Richter Syndrome
Biological study on Richter Syndrome (RS), an agressive lymphoma that arises from Chronic Lymphocytice Leukemia (CLL). RS presents with the same histological aspect as primitive Diffuse Large B-Cell Lymphoma (DLBCL), but is associated with a poor prognosis, due to chemorefractoriness. This study aims at understanding the biological determinants of chemotherapy resistance in Richter Syndrome.
With the help of the French National Research Group on CLL (FILO / French Innovative Leukemia Organization), the investigators are currently gathering fresh frozen cell pellets at CLL stage, and lymph node biopsies at Richter stage. The investigators also gathered lymph node biopsies from DLBCL, as a reference group. The investigators will perform genomic and proteomic comparative studies between CLL and Richter, as well as between Richter and primitive DLBCL, to understand the biological determinants of clonal evolution and chemorefractoriness of Richter Syndrom.
Age
All ages
Sex
ALL
Healthy Volunteers
Yes
CHRU de Nancy
Nancy, France
Start Date
September 6, 2017
Primary Completion Date
December 31, 2023
Completion Date
September 5, 2024
Last Updated
March 24, 2023
170
ESTIMATED participants
Whole exome sequencing.
GENETIC
RNA sequencing
GENETIC
Mass spectrometry
OTHER
Lead Sponsor
Central Hospital, Nancy, France
Collaborators
NCT05672173
NCT05025800
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions